Search for: "Mylan Pharmaceuticals"
Results 141 - 160
of 739
Sort by Relevance
|
Sort by Date
13 May 2019, 1:45 pm
(credit: Getty | Fred Dufour) Twenty leading drug companies—including Teva Pharmaceuticals, Pfizer, Novartis, and Mylan—were in cahoots for years to fix and dramatically inflate the prices of more than 100 generic drugs, in some cases to raising prices "well over 1,000 percent," according to a lawsuit filed late last week by 44 states. [read post]
8 May 2019, 7:14 am
” It’s not enough to put an unapproved drug on the market with a FDA-ish package insert, according to Mylan Labs., Inc. v. [read post]
13 Mar 2019, 9:10 am
Mylan Pharmaceuticals, Inc., et al., No. 18-899 (May tribal sovereign immunity may be asserted to bar IPR review of patents owned by the tribe?) [read post]
11 Mar 2019, 7:08 pm
The asymmetry of this burden is especially salient in domains like pharmaceutical drugs and biosimilars, where the incentive to test the validity of patents has important social consequences, and the complexities of those decades-long disputes create fact patterns that can be difficult to unpack. [read post]
10 Mar 2019, 4:54 am
The invention protected by the patent owned by Eli Lilly relates to a highly selective phosphodiesterase (PDE) enzyme inhibitor and to its use in a pharmaceutical unit dosage form. [read post]
21 Feb 2019, 9:29 pm
Mylan Pharmaceuticals Inc., No. 2018-2097 ("Valeant II"), Salix moves to disqualify in Salix Pharmaceuticals, Inc. v. [read post]
21 Feb 2019, 8:45 am
Mylan Pharmaceuticals Inc., No. 2018-2097 (“Valeant II”), Salix moves todisqualify in Salix Pharmaceuticals, Inc. v. [read post]
14 Feb 2019, 9:50 pm
RE38,551 challenged in inter partes review were not unpatentable for obviousness, in Mylan Pharmaceuticals Inc. v. [read post]
14 Feb 2019, 7:05 am
Mylan Pharmaceuticals Inc. 18-899 Issue: Whether inter partes review before the Patent Trial and Appeal Board is the type of proceeding in which tribal sovereign immunity may be asserted. [read post]
12 Feb 2019, 10:15 am
The Federal Circuit first visited the issue of whether three petitioners—Mylan Pharmaceuticals, Breckenridge Pharmaceuticals, and Alembic Pharmaceuticals, all of whom were sued for infringement of the patent more than one year prior to the institution of the IPR, and all of whom were joined in the IPR under 35 U.S.C. [read post]
12 Feb 2019, 10:15 am
The Federal Circuit first visited the issue of whether three petitioners—Mylan Pharmaceuticals, Breckenridge Pharmaceuticals, and Alembic Pharmaceuticals, all of whom were sued for infringement of the patent more than one year prior to the institution of the... [read post]
7 Feb 2019, 5:36 pm
In Momenta Pharmaceuticals, Inc. v. [read post]
6 Feb 2019, 5:15 pm
Statutory Right to Appeal for Joined Parties In Mylan Pharmaceuticals Inc. v. [read post]
6 Feb 2019, 5:00 am
I suppose a more salient example is Mylan's Epi-Pen, which uses a protected delivery system for a generic drug. [read post]
4 Feb 2019, 8:59 am
Obviousness: In Mylan, the Federal Circuit affirms a PTAB decision siding with the patentee and holding that RCT’s pharmaceutical compound patent claims were not proven unpatentable (i.e., confirming patentability). [read post]
23 Jan 2019, 10:08 am
Mylan Pharmaceuticals, Inc., et al. [read post]
23 Jan 2019, 9:58 am
Mylan Pharmaceuticals, Inc., et al. [read post]
23 Jan 2019, 9:58 am
Mylan Pharmaceuticals, Inc., et al. [read post]
22 Jan 2019, 6:15 am
Mylan Pharmaceuticals petitioned for IPR of the ‘650 patent alleging certain claims were obvious. [read post]
22 Jan 2019, 6:15 am
Mylan Pharmaceuticals petitioned for IPR of the ‘650 patent alleging certain claims were obvious. [read post]
